Psychedelic Medicine

Association

Psilocybin in pharmacotherapy of obsessive-compulsive disorder

Excerpts from the publication

Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early maladaptive schemas seem of importance. Pharmacological treatment includes drugs affecting the serotoninergic, dopaminergic, and glutamatergic systems, such as selective serotonin reuptake inhibitors (SSRIs). Providing that up to 40% of patients with OCD are resistant to the currently available medications, there is a need for novel and effective therapies. Recent discoveries suggest that psilocybin, a non-physically addictive psychoactive substance, may ameliorate disease symptoms. When used in appropriate doses and under strict clinical control, psilocybin appears as a valuable treatment for OCD. This narrative article provides a thorough overview of OCD’s etiology, current treatment options, and the emerging evidence supporting psilocybin’s efficacy in managing OCD symptoms.

Read more

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database

The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis

MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study

Are psychedelics the answer to chronic pain: A review of current literature

Application of Ketamine in Pain Management and the Underlying Mechanism